Calidi Biotherapeutics (CLDI) vs HCW Biologics (HCWB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Calidi Biotherapeutics is the larger company by market cap ($3.9 million vs $3.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLDI | HCWB |
|---|---|---|
| Share price | $1.05 | $1.65 |
| Market cap | $3.86M | $3.69M |
| 1-day change | +0.96% | +7.84% |
| EPS (TTM) | $-36.47 | $-19.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.84 | $27.57 |
| 52-week low | $0.986 | $1.50 |
| Distance from 52-week high | -96.23% | -94.02% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +2809.09% |
| Average volume | 255.53K | 376.23K |
| Shares outstanding | 3.68M | 2.24M |
| Employees | 29 | 35 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Calidi Biotherapeutics
CLDI stock →Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 29 employees
About HCW Biologics
HCWB stock →HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees
CLDI vs HCWB FAQ
Which is bigger, Calidi Biotherapeutics or HCW Biologics?
Calidi Biotherapeutics (CLDI) is larger, with a market capitalization of $3.86M compared with $3.69M for HCW Biologics (HCWB).
Are Calidi Biotherapeutics and HCW Biologics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Calidi Biotherapeutics and Biotechnology: Pharmaceutical Preparations for HCW Biologics.